Stage‐specific impact of pelvic lymph node dissection on survival in patients with non‐metastatic bladder cancer treated with radical cystectomy
Open Access
- 24 August 2011
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 109 (8) , 1147-1154
Abstract
Study Type – Therapy (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? In patients treated with radical cystectomy, pelvic lymph node dissection may have a beneficial effect on cancer control outcomes. We examined the effect of pelvic lymph node dissection on stage‐specific cancer control outcomes. OBJECTIVE: To examine the effect of stage‐specific pelvic lymph node dissection (PLND) on cancer‐specific (CSM) and overall mortality (OM) rates at radical cystectomy (RC) for bladder cancer. METHODS: Overall, 11 183 patients were treated with RC within the Surveillance, Epidemiology, and End Results database. Univariable and multivariable Cox regression analyses tested the effect of PLND on CSM and OM rates, after stratifying according to pathological tumour stage. RESULTS: Overall, PLND was omitted in 25% of patients, and in 50, 35, 27, 16 and 23% of patients with respectively pTa/is, pT1, pT2, pT3 and pT4 disease ( P < 0.001). For the same stages, the 10‐year CSM‐free rates for patients undergoing PLND compared with those with no PLND were, respectively, 80 vs 71.9% ( P = 0.02), 81.7 vs 70.0% ( P < 0.001), 71.5 vs 56.1% ( P = 0.001), 43.7 vs 38.8% ( P = 0.006), and 35.1 vs 32.0% ( P = 0.1). In multivariable analyses, PLND omission was associated with a higher CSM in patients with pTa/is, pT1 and pT2 disease (all P ≤ 0.01), but failed to achieve independent predictor status in patients with pT3 and pT4 disease (both P ≥ 0.05). Omitting PLND predisposed to a higher OM across all tumour stages (all P ≤ 0.03). CONCLUSIONS: Our results indicate that PLND was more frequently omitted in patients with organ‐confined disease. The beneficial effect of PLND on cancer control outcomes was more evident in these patients than in those with pT3 or pT4 disease. PLND at RC should always be considered, regardless of tumour stage.Keywords
This publication has 8 references indexed in Scilit:
- Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: An overviewUrologic Oncology: Seminars and Original Investigations, 2012
- Trends in Pelvic Lymphadenectomy at the Time of Radical Cystectomy: 1988 to 2004Journal of Urology, 2009
- Indications, Extent, and Benefits of Pelvic Lymph Node Dissection for Patients with Bladder and Prostate CancerThe Oncologist, 2009
- The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomyCancer, 2008
- Outcome After Radical Cystectomy With Limited or Extended Pelvic Lymph Node DissectionJournal of Urology, 2008
- Lymphadenectomy in Bladder Cancer: A ReviewUrologia Internationalis, 2007
- Surgical Factors Influence Bladder Cancer Outcomes: A Cooperative Group ReportJournal of Clinical Oncology, 2004
- Extent of Pelvic Lymphadenectomy and Its Impact On Outcome in Patients Diagnosed With Bladder Cancer: Analysis of Data From the Surveillance, Epidemiology and End Results Program Data BaseJournal of Urology, 2003